Related Experiment Video

Updated: Jul 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pediatric heart tumors

Allen Burke1, Renu Virmani

  • 1CVPath Institute, Gaithersburg, MD 20878, USA. aburke1029@mac.com

Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology
|April 12, 2008
PubMed

Insights

Pediatric heart tumors, mainly benign hamartomas like rhabdomyoma and fibroma, are rare but can cause serious health issues. While some regress, their size and location are critical for patient outcomes.

Area of Science:

  • Pediatric Cardiology
  • Pediatric Oncology
  • Cardiac Pathology

Background:

  • Heart tumors in children are uncommon.
  • Most pediatric heart tumors are benign hamartomas (rhabdomyoma, fibroma) with potential for spontaneous regression.
  • Despite their benign nature, these tumors can cause significant morbidity and mortality due to size and cardiac location.

Purpose of the Study:

  • To review the characteristics of various pediatric heart tumors.
  • To discuss the clinical implications of both common and rare cardiac tumors in children.
  • To highlight the diagnostic and management considerations for these rare conditions.

Main Methods:

  • Literature review of pediatric cardiac tumors.
  • Analysis of tumor types, including hamartomas, histiocytoid cardiomyopathy, hemangiomas, germ cell tumors, and sarcomas.
  • Discussion of clinical presentation, pathology, and outcomes.

Main Results:

  • Rhabdomyomas and fibromas are the most frequent pediatric heart tumors and often regress spontaneously.
  • Other rare cardiac tumors in children include histiocytoid cardiomyopathy, hemangioma, germ cell tumors, and sarcomas.
  • Tumor size and location are key determinants of clinical impact.

Conclusions:

  • While most pediatric heart tumors are benign hamartomas, they require careful monitoring due to potential complications.
  • A spectrum of rare cardiac tumors exists in children, necessitating a broad differential diagnosis.
  • Understanding the behavior and impact of these tumors is crucial for effective pediatric cardiac care.

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...